WALTHAM, Mass.--(BUSINESS WIRE)--
PerkinElmer,
Inc. (NYSE: PKI), a global leader committed to innovating for a
healthier world, today announced that the company has completed the sale
of its Medical Imaging business to Varex
Imaging Corporation (Nasdaq: VREX).
PerkinElmerannounced
its intent to sell its Medical Imaging business, a supplier of flat
panel X-ray detectors that serve as components for industrial, medical
and dental X-ray imaging systems, on December 22, 2016.
"The sale of Medical Imaging supports our strategy of redirecting our
investments towards accelerating growth in key markets," said Robert
Friel, Chairman and Chief Executive Officer, PerkinElmer.
About PerkinElmer
PerkinElmer, Inc. is a global leader
focused on innovating for a healthier world. The Company reported
revenue of approximately $2.1 billion in 2016, has about 9,000 employees
serving customers in more than 150 countries, and is a component of the
S&P 500 Index. Additional information is available through
1-877-PKI-NYSE, or at www.perkinelmer.com.
Factors Affecting Future Performance
This press release contains "forward-looking" statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements relating to estimates and
projections of future earnings per share, cash flow and revenue growth
and other financial results, developments relating to our customers and
end-markets, and plans concerning business development opportunities and
divestitures. Words such as "believes," "intends," "anticipates,"
"plans," "expects," "projects," "forecasts," "will" and similar
expressions, and references to guidance, are intended to identify
forward-looking statements. Such statements are based on management's
current assumptions and expectations and no assurances can be given that
our assumptions or expectations will prove to be correct. A number of
important risk factors could cause actual results to differ materially
from the results described, implied or projected in any forward-looking
statements. These factors include, without limitation: (1) markets into
which we sell our products declining or not growing as anticipated; (2)
fluctuations in the global economic and political environments; (3) our
failure to introduce new products in a timely manner; (4) our ability to
execute acquisitions and license technologies, or to successfully
integrate acquired businesses and licensed technologies into our
existing business or to make them profitable, or successfully divest
businesses; (5) our failure to adequately protect our intellectual
property; (6) the loss of any of our licenses or licensed rights; (7)
our ability to compete effectively; (8) fluctuation in our quarterly
operating results and our ability to adjust our operations to address
unexpected changes; (9) significant disruption in third-party package
delivery and import/export services or significant increases in prices
for those services; (10) disruptions in the supply of raw materials and
supplies; (11) the manufacture and sale of products exposing us to
product liability claims; (12) our failure to maintain compliance with
applicable government regulations; (13) regulatory changes; (14) our
failure to comply with healthcare industry regulations; (15) economic,
political and other risks associated with foreign operations; (16) our
ability to retain key personnel; (17) significant disruption in our
information technology systems; (18) our ability to obtain future
financing; (19) restrictions in our credit agreements; (20) the approval
of the Brexit Referendum in the United Kingdom; (21) our ability to
realize the full value of our intangible assets; (22) significant
fluctuations in our stock price; (23) reduction or elimination of
dividends on our common stock; and (24) other factors which we describe
under the caption "Risk Factors" in our most recent annual report on
Form 10-K and in our other filings with the Securities and Exchange
Commission. We disclaim any intention or obligation to update any
forward-looking statements as a result of developments occurring after
the date of this press release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170501006261/en/
PerkinElmer, Inc.
Investor Relations:
Tommy J. Thomas,
781-663-5889
tommy.thomas@perkinelmer.com
or
Media:
Brian
Willinsky, 781-663-5728
brian.willinsky@perkinelmer.com
Source: PerkinElmer, Inc.
News Provided by Acquire Media